Literature DB >> 15319715

Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).

Felix G Fernandez1, Jeffrey A Drebin, David C Linehan, Farrokh Dehdashti, Barry A Siegel, Steven M Strasberg.   

Abstract

OBJECTIVE: To report the first 5-year overall survival results in patients with colorectal carcinoma metastatic to the liver who have undergone hepatic resection after staging with [18F] fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). SUMMARY BACKGROUND DATA: The 5-year overall survival after hepatic resection for colorectal cancer metastases without preoperative FDG-PET has been established in 19 studies (6070 patients). The median 5-year overall survival rate in these studies is 30% and has not improved over time. FDG-PET detects unsuspected tumor in 25% of patients considered to have resectable hepatic metastasis by conventional staging.
METHODS: From March 1995 to June 2002, all patients having hepatic resection for colorectal cancer metastases had preoperative FDG-PET. A prospective database was maintained.
RESULTS: One hundred patients (56 men, 44 women) were studied. Metastases were synchronous in 52, single in 63, unilateral in 78, and <5 cm in diameter in 60. Resections were major (>3 segments) in 75 and resection margins were > or = 1 cm in 52. Median follow up was 31 months, with 12 actual greater than 5-year survivors. There was 1 postoperative death. The actuarial 5-year overall survival was 58% (95% confidence interval, 46-72%). Primary tumor grade was the only prognostic variable significantly correlated with overall survival.
CONCLUSIONS: Screening by FDG-PET is associated with excellent postresection 5-year overall survival for patients undergoing resection of hepatic metastases from colorectal cancer. FDG-PET appears to define a new cohort of patients in whom tumor grade is a very important prognostic variable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319715      PMCID: PMC1356434          DOI: 10.1097/01.sla.0000138076.72547.b1

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  47 in total

1.  FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.

Authors:  Max Lonneux; Abdel-Malek Reffad; Roger Detry; Alex Kartheuser; Jean-François Gigot; Stanislas Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-04-13       Impact factor: 9.236

2.  Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results.

Authors:  M Minagawa; M Makuuchi; G Torzilli; T Takayama; S Kawasaki; T Kosuge; J Yamamoto; H Imamura
Journal:  Ann Surg       Date:  2000-04       Impact factor: 12.969

3.  Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.

Authors:  S M Strasberg; F Dehdashti; B A Siegel; J A Drebin; D Linehan
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

4.  Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis.

Authors:  M Lise; S Bacchetti; P Da Pian; D Nitti; P Pilati
Journal:  World J Surg       Date:  2001-05       Impact factor: 3.352

5.  Hepatic resection for colorectal liver metastases: prospective study.

Authors:  C L Liu; S T Fan; C M Lo; W L Law; I O L Ng; J Wong
Journal:  Hong Kong Med J       Date:  2002-10       Impact factor: 2.227

6.  Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma.

Authors:  N Kokudo; K Tada; M Seki; H Ohta; K Azekura; M Ueno; T Matsubara; T Takahashi; T Nakajima; T Muto
Journal:  Am J Surg       Date:  2001-02       Impact factor: 2.565

7.  [Resection of colorectal liver metastases. What prognostic factors determine patient selection?].

Authors:  J Scheele; A Altendorf-Hofmann; T Grube; W Hohenberger; R Stangl; K Schmidt
Journal:  Chirurg       Date:  2001-05       Impact factor: 0.955

Review 8.  A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma.

Authors:  Annelore Altendorf-Hofmann; Johannes Scheele
Journal:  Surg Oncol Clin N Am       Date:  2003-01       Impact factor: 3.495

9.  Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions.

Authors:  Tomoyuki Kato; Kenzo Yasui; Takashi Hirai; Yukihide Kanemitsu; Takeo Mori; Kenichi Sugihara; Hidetaka Mochizuki; Junji Yamamoto
Journal:  Dis Colon Rectum       Date:  2003-10       Impact factor: 4.585

10.  Resection of colorectal liver metastases.

Authors:  J Scheele; R Stang; A Altendorf-Hofmann; M Paul
Journal:  World J Surg       Date:  1995 Jan-Feb       Impact factor: 3.352

View more
  154 in total

1.  Clinical risk score can be used to select patients for staging laparoscopy and laparoscopic ultrasound for colorectal liver metastases.

Authors:  A J Shah; J Phull; M D Finch-Jones
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

2.  Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases.

Authors:  Eduardo de Santibañes; Diego Fernandez; Carlos Vaccaro; Guillermo Ojea Quintana; Fernando Bonadeo; Juan Pekolj; Carlos Bonofiglio; Ernesto Molmenti
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 3.  The surgical treatment of hepatic metastases in colorectal carcinoma.

Authors:  Ulf Peter Neumann; Daniel Seehofer; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2010-05-14       Impact factor: 5.594

4.  Recent advances in the curative treatment of colorectal liver metastases.

Authors:  Andreas Andreou; Thomas A Aloia; Antoine Brouquet; Jean-Nicolas Vauthey
Journal:  Gastrointest Cancer Res       Date:  2011-07

Review 5.  Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome.

Authors:  George A Poultsides; Richard D Schulick; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

6.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

Review 7.  The role of targeted therapy in the treatment of advanced colorectal cancer.

Authors:  Marwan Fakih
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

8.  Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases?

Authors:  Nir Lubezky; Ravit Geva; Einat Shmueli; Richard Nakache; Joseph M Klausner; Arie Figer; Menahem Ben-Haim
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

9.  Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Elena Panettieri; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2019-05-02       Impact factor: 6.113

10.  Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Authors:  Markus Selzner; Thomas F Hany; Peer Wildbrett; Lucas McCormack; Zakiyah Kadry; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.